Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Vertex Pharmaceuticals's average EPS without NRI Growth Rate was 12.30% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 7.30% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -19.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Vertex Pharmaceuticals was 84.40% per year. The lowest was -96.70% per year. And the median was -1.25% per year.
Vertex Pharmaceuticals (MEX:VRTX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Vertex Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms
MEX:VRTX vs REGN, MRNA, RVMD: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.
Vertex Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 7.30% mean?
Vertex Pharmaceuticals (MEX:VRTX) has a 3-Year EPS without NRI Growth Rate of 7.30% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Vertex Pharmaceuticals and its competitors. According to the industry distribution chart, Vertex Pharmaceuticals ranks #714 out of 1159 companies in the Biotechnology industry, placing it in the top 61.6%.
Is Vertex Pharmaceuticals' 3-Year EPS without NRI Growth Rate too high?
Vertex Pharmaceuticals' current 3-Year EPS without NRI Growth Rate is 7.30%. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Vertex Pharmaceuticals' value of 7.30% is 54.9% below this industry median. Based on the distribution chart, Vertex Pharmaceuticals ranks #714 out of 1159 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vertex Pharmaceuticals has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' 3-Year EPS without NRI Growth Rate compare to REGN and MRNA?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #714 out of 1159 companies for 3-Year EPS without NRI Growth Rate. This places Vertex Pharmaceuticals in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Vertex Pharmaceuticals' value of 7.30% is 54.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,159 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vertex Pharmaceuticals's current 3-Year EPS without NRI Growth Rate of 7.30% is 54.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Vertex Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vertex Pharmaceuticals's current 3-Year EPS without NRI Growth Rate is 7.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN8,838.46, compared to a current price of MXN9,212.00 — trading 4.2% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 7.30% and 54.9% below the Biotechnology industry median of 16.20. Vertex Pharmaceuticals' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current 3-Year EPS without NRI Growth Rate is 7.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN9,212.00 is trading 4.2% above its estimated GF Value™ of MXN8,838.46.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:VRTX:
3-Year EPS without NRI Growth Rate: 7.30%
GF Value™: MXN8,838.46 vs. price of MXN9,212.00 (4.2% above fair value)
Industry Position: 54.9% below the Biotechnology median (#714 of 1159)
No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
88GF Score
Get the complete analysis for MEX:VRTX
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VRTX has been successfully added to your 
